Preview Mode Links will not work in preview mode

Jul 2, 2019

A virtual roundtable discussion with noted investigators Prof Meletios A Dimopoulos and Dr Steven P Treon for a review of recent innovations in the treatment of Waldenström Macroglobulinemia.

  • Pathophysiology, symptoms and common genetic mutations associated with Waldenström macroglobulinemia (WM) (00:00)
  • Somatic mutations in MYD88 (L265P) and CXCR4 and implications for prognosis and therapy (1:46)
  • Diagnostic criteria for WM (7:12)
  • Case (Dr Treon): A man in his late 60s with WM experiences an IgM flare and worsening peripheral neuropathy during first-line treatment with rituximab (8:55)
  • Indications for the initiation of therapy for patients with WM (12:02)
  • Management approach for patients with WM experiencing IgM flare after treatment with rituximab (13:40)
  • Activity of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib alone or in combination with rituximab in patients with WM (15:35)
  • Perspective on the use of ibrutinib with or without rituximab as front-line therapy for WM (17:51)
  • Symptoms and management of hyperviscosity syndrome associated with WM (21:07)
  • Role of obinutuzumab in the management of WM (23:58)
  • Case (Prof Dimopoulos): A man in his early 50s with WM and a MYD88 L265P mutation attains a very good partial response to first-line therapy with bortezomib/dexamethasone/rituximab (25:24)
  • Selection of therapy for patients with WM in the first-line setting (27:50)
  • Efficacy and tolerability of proteasome inhibitors for WM (31:42)
  • Peripheral neuropathy associated with WM and implications for therapy (34:39)
  • Duration of ibrutinib therapy for WM and impact of treatment holidays (37:27)
  • Side effects associated with ibrutinib; monitoring and management of atrial fibrillation (39:44)
  • Case (Dr Treon): A woman in her mid-60s diagnosed with WM and a MYD88 L265P mutation experiences a dramatic response after receiving ibrutinib as first-line therapy (44:44)
  • Response and tolerability with ibrutinib in the front-line setting (46:56)
  • Case (Prof Dimopoulos): A woman in her early 80s with a history of hypertension and atrial fibrillation is diagnosed with WM with a MYD88 L265P mutation and receives ibrutinib and anticoagulation therapy (49:39)
  • Perspective on the use of ibrutinib for elderly patients and those with a history of atrial fibrillation (51:37)
  • Activity of the BTK inhibitor zanubrutinib in patients with WM (54:36)
  • Results of the Phase III iNNOVATE trial evaluating ibrutinib with rituximab versus rituximab alone for patients with previously untreated or relapsed/refractory WM (56:19)
  • Ongoing investigation of CXCR4 inhibitors and the Bcl-2 inhibitor venetoclax for WM (57:59)
  • Biologic rationale and role for venetoclax in WM (1:00:28)
  • Tumor lysis syndrome associated with venetoclax  (1:04:11)
  • Novel agents and approaches under investigation for WM (1:05:26)
  • Therapeutic options for patients with WM after disease progression on ibrutinib (1:06:56)

Select publications